Common Mutations Could Lead to Targeted Treatment for Patients with Brain Metastases

Currently, scientists have a limited understanding of how brain metastases genetically evolve from their primary tumor, making them difficult to treat. However, research presented at the Society for Neuro-Oncology’s Annual Meeting may have identified a connection between genetic mutations and treatment options that could offer patients improved outcomes.



OncLive®, CURE®’s sister publication, spoke with Dr. Priscilla Brastianos, director of the Central Nervous System Metastasis Program at Massachusetts General Hospital, about how CDK pathway alterations could lead to more targeted treatment.


View more at



CURE: Combining science and humanity to make cancer understandable.

cancer,oncology,cancer care,cure magazine,health,